<DOC>
	<DOCNO>NCT02672995</DOCNO>
	<brief_summary>The investigator propose new treatment strategy fractionate stereotactic radiosurgery concurrent bevacizumab brain metastasis . This phase I dose-escalation study establish feasibility strategy find recommended dos .</brief_summary>
	<brief_title>Fractionated Stereotactic Radiosurgery With Concurrent Bevacizumab Brain Metastases : A Phase I Dose-escalation Trial</brief_title>
	<detailed_description>For group ( two group accord tumor size ) , design proceeds cohort three patient , first cohort treat start dose . If none three patient cohort experience dose-limiting toxicity ( DLT ) , next cohort three patient treat next high dose level . If one first three patient experience dose-limiting toxicity , next cohort treat dose level . The dose escalation continue least two patient among cohort three six patient experience DLTs maximum tolerate dose ( MTD ) dose level . If high plan dose achieve without two patient experience DLTs , MTD dose level . The DLT define grade 4 toxicity accord Common Terminology Criteria Adverse Events ( CTCAE ) version 4.03 within 4 month stereotactic radiosurgery ( SRS ) : Grade 4 central nervous system necrosis ( life-threatening consequence ; urgent intervention indicate ) Grade 4 sensory motor neuropathy ( life-threatening consequence ; urgent intervention indicate ) Grade 4 hemorrhage ( life-threatening consequence ; urgent intervention indicate ) Grade 4 thromboembolic event ( life-threatening consequence pulmonary embolism , cerebrovascular event , arterial insufficiency ; hemodynamic neurologic instability ; urgent intervention indicate ) Grade 4 hypertension ( life-threatening consequence malignant hypertension , transient permanent neurologic deficit , hypertensive crisis ; urgent intervention indicate ) Study treatment : Fractionated stereotactic radiosurgery : Group 1 : tumor 1.5~2.5 cm diameter Dose level 1 : 21 Gy 3 fraction Dose level 2 : 24 Gy 3 fraction Dose level 3 : 27 Gy 3 fraction Group 2 : tumor 2.5~3.5 cm diameter Dose level 1 : 18 Gy 3 fraction Dose level 2 : 21 Gy 3 fraction Dose level 3 : 24 Gy 3 fraction Three fraction give one week least 1 day break . Concurrent bevacizumab : Bevacizumab 7.5 mg/kg give one day first fraction radiosurgery 2 week first dose bevacizumab .</detailed_description>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Inclusion criterion To eligible inclusion , patient must fulfill follow criterion : 1 . Patients histologic diagnosis nonhematopoietic malignancy radiographic evidence measurable brain metastasis ( 1.5~3.5 cm ) . 2 . The number brain metastasis receive fractionate SRS : ≤3 . 3 . No evidence leptomeningeal metastasis gadoliniumenhanced MRI within 30 day prior registration . 4 . Age ≥ 20 year . 5 . Karnofsky Performance Status ≥ 60 . 6 . Life expectancy ≥ 4 month . 7 . Women childbearing potential male participant must practice adequate contraception . 8 . Patients must able comply study protocol followup schedule provide studyspecific inform consent . Exclusion criteria Patients fulfill follow criterion exclude trial 1 . Serum creatinine &gt; 2.0 mg/dL within 30 day prior registration 2 . Contraindication magnetic resonance ( MR ) image implant metal device foreign body , severe claustrophobia 3 . Patients evidence bleed diathesis coagulopathy , international normalize ratio ( INR ) &gt; 1.5 4 . Patients require use warfarin sodium &gt; 1 mg 5 . Patients active GI ulcer , GI bleeding , active inflammatory bowel disease 6 . Patients clinically significant cardiac disease ( e.g. , uncontrolled hypertension [ blood pressure &gt; 160/90 mmHg medication ] , history myocardial infarction unstable angina within 12 month registration ) , New York Heart Association ( NYHA ) Class II great congestive heart failure , unstable symptomatic arrhythmia require medication ( subject chronic atrial arrhythmia , i.e. , atrial fibrillation paroxysmal supraventricular tachycardia ) eligible 7 . Patients history aneurysm , cerebrovascular accident ( CVA ) arteriovenous malformation 8 . Patients arterial thromboembolic event , include transient ischemic attack ( TIA ) , clinically significant peripheral artery disease within 6 month registration 9 . Patients serious , nonhealing wound , ulcer , current healing fracture 10 . Patients history type fistula ( vesicovaginal , gastrointestinal , etc ) gastrointestinal perforation 11 . Severe , active comorbidities , judgment investigator , would make patient inappropriate entry study interfere significantly proper assessment safety adverse event protocol , limit compliance study requirement , define follow : 1 . Uncontrolled active infection require intravenous antibiotic time registration 2 . Transmural myocardial infarction ≤ 6 month prior registration 3 . Hepatic insufficiency result clinical jaundice and/or coagulation defect 4 . Chronic obstructive pulmonary disease exacerbation respiratory illness require hospitalization preclude study therapy time registration 5 . Uncontrolled psychiatric disorder 12 . Will receive investigational agent chemotherapy and/or target therapy SRS 13 . Women childbearing potential male participant sexually active willing/able use medically acceptable form contraception ; exclusion necessary radiation treatment involve study may significantly teratogenic</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>stereotactic radiosurgery , Bevacizumab</keyword>
</DOC>